BRIEF published on 04/10/2025 at 07:05, 1 year 7 months ago Relief Therapeutics annonce ses résultats financiers et ses progrès stratégiques pour 2024 Biopharmaceutique Maladies Rares THÉRAPEUTIQUE DE SECOURS Résultats Financiers 2024 Progrès Du Pipeline
PRESS RELEASE published on 04/10/2025 at 07:00, 1 year 7 months ago Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports 2024 financial results and provides a corporate update, emphasizing operational achievements, pipeline momentum, and strengthened financial position Biopharmaceutical Corporate Update Relief Therapeutics Rare Diseases 2024 Financial Results
BRIEF published on 03/06/2025 at 07:05, 1 year 8 months ago Relief Therapeutics Ends Merger Discussions with Renexxion Shareholder Value Relief Therapeutics Strategic Objectives Renexxion Merger Termination
BRIEF published on 03/06/2025 at 07:05, 1 year 8 months ago Relief Therapeutics met fin aux discussions de fusion avec Renexxion Valeur Actionnariale Objectifs Stratégiques THÉRAPEUTIQUE DE SECOURS Renexxion Fin De La Fusion
PRESS RELEASE published on 03/06/2025 at 07:00, 1 year 8 months ago Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion Relief Therapeutics terminates merger discussions with Renexxion after failing to meet key conditions. Company remains well-positioned with robust pipeline and cash reserves Relief Therapeutics Cash Reserves Therapeutic Pipeline Renexxion Merger Discussions
BRIEF published on 02/11/2025 at 07:05, 1 year 8 months ago European Patent Office Grants Relief Therapeutics Patent for RLF-TD011 Biopharmaceuticals Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa
BRIEF published on 02/11/2025 at 07:05, 1 year 8 months ago L'Office européen des brevets accorde un brevet thérapeutique de secours pour le RLF-TD011 Produits Biopharmaceutiques THÉRAPEUTIQUE DE SECOURS RLF-TD011 Brevet Européen Epidermolyse Bulleuse
PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 8 months ago Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Relief Therapeutics obtains European Patent Office grant for RLF-TD011, securing patent protection for epidermolysis bullosa treatment. Company advances wound care solution Relief Therapeutics European Patent Office Epidermolysis Bullosa Wound Treatment RLD-TD011
BRIEF published on 01/22/2025 at 07:05, 1 year 9 months ago Relief Therapeutics Sells GOLIKE Rights, Shifts Focus to R&D Relief Therapeutics GOLIKE Sale Nutrisens Partnership Biopharmaceutical Strategy R&D Focus
BRIEF published on 01/22/2025 at 07:05, 1 year 9 months ago Relief Therapeutics vend les droits de GOLIKE et se concentre sur la R&D THÉRAPEUTIQUE DE SECOURS Vente GOLIKE Partenariat Nutrisens Stratégie Biopharmaceutique Focus R&D
Published on 11/10/2026 at 02:45, 5 hours 24 minutes ago Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:10, 8 hours 59 minutes ago Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 9 hours 9 minutes ago LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 9 hours 37 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/09/2026 at 22:15, 9 hours 54 minutes ago Goldcliff Announces Closing of the Second and Final Tranche of its "LIFE" Offering and Completion of Drilling at Kettle Valley
Published on 11/10/2026 at 07:50, 18 minutes ago From veranda to garden room: enjoy your garden all year round
Published on 11/10/2026 at 07:50, 19 minutes ago Turkiye Garanti Bankasi A.S.: Daily Share Buyback Transactions
Published on 11/10/2026 at 07:45, 23 minutes ago Telecom Review Group Accelerates the Journey to 10Giga GCC with U6GHz
Published on 11/10/2026 at 07:38, 30 minutes ago Elmos Semiconductor SE continues profitable growth and strong cash generation in the third quarter of 2026
Published on 11/10/2026 at 07:30, 38 minutes ago Henkel posts very strong sales growth in the third quarter
Published on 11/10/2026 at 07:00, 1 hour 9 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/10/2026 at 07:00, 1 hour 9 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine et le marquage CE selon l’IVDR pour VITEK® PRO, son nouvel instrument automatisé d’identification et d’antibiogramme contribuant à la lutte contre l’antibiorésistance
Published on 11/09/2026 at 18:30, 13 hours 39 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 13 hours 39 minutes ago Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
